Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

By J. Emile, O. Abla, S. Fraitag, A. Horne, J. Haroche, J. Donadieu, L. Requena-Caballero, M. Jordan, O. Abdel-Wahab, C. Allen and 14 more. Blood, 2016

1,389 citations recorded by the source corpus.

Subfields: Infectious Diseases, Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/03d6948e50145d1d18dd294caabffe1fe9dca7f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Andreas Hochhaus
2. J. Apperley
3. H. Kantarjian
4. O. Abla
5. Elisabet Bergsten
6. J. Khoury
7. R. Bejar
8. M. Aricò

Citations in the corpus

• Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. (2017, background): “” The information in this section suggests that treatment possibly should be (1) risk group stratified and (2) less aggressive days 11 to 42 for some patients, and (3) with less reduction of initial treatment days 43 to 59 for verified FHL patients.”
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022, background): “Nonetheless, there are rare cases that show overlap or hybrid features, defying precise classification [98, 99].”